Becton Dickinson & Company Celebrates 1,000th BD Rhapsody™ System Installation at Cambridge University
- Becton Dickinson installed its 1,000th BD Rhapsody™ System at the University of Cambridge, enhancing single-cell analysis capabilities.
- The BD Rhapsody™ System has been referenced in over 700 publications, demonstrating its significant impact on scientific research.
- BD's commitment to innovation is highlighted by the successful integration of the BD Rhapsody™ System with other BD instruments.
BD Rhapsody™ System Reaches Milestone at University of Cambridge, Enhancing Single-Cell Analysis
Becton, Dickinson and Company (BD), a leader in global medical technology, marks a significant milestone with the installation of its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital, University of Cambridge. This cutting-edge system, designed for single-cell multiomics analysis, revolutionizes how scientists analyze and interpret data from individual cells. Installed on September 17, 2025, the BD Rhapsody™ System is pivotal for advancing research into immune cell signaling pathways, particularly in critically ill patients. Dr. Andrew Conway Morris, an associate professor at Addenbrooke's, highlights the system's potential to translate complex cellular data into actionable treatment strategies aimed at improving patient outcomes in critical care.
Since its debut in 2017, the BD Rhapsody™ System has made a significant impact on the scientific community, being referenced in over 700 peer-reviewed publications. This extensive use underscores the system's role in facilitating cutting-edge research and enhancing our understanding of cellular behavior. The latest version, introduced in 2023, boasts enhanced sample processing capabilities and improved cell capture through innovative microwell-based cartridge technology, which allows for more effective library preparations for next-generation sequencing. This advancement not only streamlines workflows but also accelerates the pace of research, enabling scientists to derive insights from vast amounts of data more efficiently.
Ranga Partha, PhD, Vice President of global marketing and strategic growth at BD Biosciences, comments on the increasing demand for high-performing single-cell platforms. He notes that the BD Rhapsody™ System strikes a balance between the complexity of multiomic assays and the quality of data at an affordable cost per cell. This milestone installation at a prestigious institution like the University of Cambridge reinforces BD's dedication to advancing medical technology and supporting innovative research initiatives across the healthcare sector.
In addition to its standalone capabilities, the BD Rhapsody™ System integrates seamlessly with other BD instruments, such as the BD FACSDiscover™ S8 Cell Sorter and A8 Cell Analyzer, further enriching the cell sorting and analysis workflows. The synergy between these systems enhances their overall functionality, empowering researchers to harness multi-dimensional data in their investigations.
The achievement of installing the 1,000th BD Rhapsody™ System not only signifies a technological milestone for BD but also highlights the company's commitment to innovation in medical technology, underscoring its role as a key player in the evolving landscape of healthcare research.